IP Library Granted Patent US 9,226,907
Granted Patent B2
US 9,226,907 · App. 12/365,639 · Granted Jan 5, 2016

Extended release hydrocodone acetaminophen and related methods and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,226,907
App. No.
12/365,639
Granted
Jan 5, 2016
Kind
B2
Abstract

The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily.

Claims (5)

1. A method of treating osteoarthritic pain, or lower back pain in a patient in need thereof, wherein the method comprises administering at least one or two dosage form to the patient comprising about 30 mg of hydrocodone and its salt and about 1000 mg of acetaminophen, once, twice or thrice daily, wherein the dosage form comprises a monoeximic pharmaceutical composition, wherein hydrocdone Cmax is less than 25 ng/ml, and wherein co-administration of about 240 ml of 40%, 20%, 4% and 0% ethanol on the single dosage form affects the mean maximum plasma concentration level Cmax by ≦25% for both hydrocodone and acetaminophen in the patient.

2. The method according to claim 1 , wherein said dosage form may be taken by the patient with or without food.

3. The method according to claim 1 , wherein no overall statistical differences in effectiveness is observed for the patient metabolizing hydrocodone when the patient is a poor or competent metabolizer of Cytochrome P450 2D6.

4. The method according to claim 1 , wherein administration of the dosage form improves a quality of life in the patient.

5. The method according to claim 1 , wherein administration of the dosage form reduces loss of productivity in the patient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030237/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2009
From: JAIN, RITA I.; BEST, ANDREA E.; LOCKHART, EARLE; MARX, STEVEN E.; THOMAS, JAMES W.; VO, PAMELA GIANG
To: ABBOTT LABORATORIES
Reel/Frame 023264/0768 →